November 5, 2019 / 11:39 AM / 8 days ago

Regeneron profit rises nearly 13% on higher demand for eczema drug Dupixent

Nov 5 - Regeneron Pharmaceuticals Inc reported a 12.6% rise in third-quarter profit on Tuesday, boosted by higher sales of its eczema drug, Dupixent.

Net income rose to $669.6 million, or $5.86 per share, in the quarter ended Sept. 30, from $594.7 million, or $5.17 per share, a year earlier.

Total revenue rose 23.1% to $2.05 billion. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below